[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.176.107. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
October 17, 2001

Ipriflavone and Osteoporosis

Author Affiliations
 

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor

JAMA. 2001;286(15):1836-1837. doi:10.1001/jama.286.15.1833

To the Editor: Dr Alexandersen and colleagues1 found that ipriflavone, which is available as an over-the-counter product, was ineffective at preventing bone loss in postmenopausal white women. We have several concerns about the study's design.

First, each of the women in the study had osteoporosis, with a bone density T score of 0.86 or less. They were each given 500 mg/d of supplemental calcium, which is well below the recommended dose of 1500 mg/d for women with osteoporosis. Also, because there is a wide range of calcium absorption from different available preparations, the specific calcium product must also be known to ensure adequate calcium intake.

First Page Preview View Large
First page PDF preview
First page PDF preview
×